Call Options

7 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2024

May 13, 2024

SELL
$56.27 - $73.77 $12.1 Million - $15.8 Million
-214,700 Reduced 92.46%
17,500 $1.21 Million
Q4 2023

Feb 13, 2024

BUY
$59.06 - $75.72 $6.24 Million - $8 Million
105,700 Added 83.56%
232,200 $17.2 Million
Q3 2023

Nov 14, 2023

BUY
$65.94 - $99.04 $1.44 Million - $2.16 Million
21,800 Added 20.82%
126,500 $8.63 Million
Q2 2023

Aug 14, 2023

BUY
$62.68 - $95.05 $2.88 Million - $4.36 Million
45,900 Added 78.06%
104,700 $9.83 Million
Q1 2023

May 15, 2023

SELL
$47.19 - $70.77 $2.59 Million - $3.88 Million
-54,800 Reduced 48.24%
58,800 $3.99 Million
Q4 2022

Sep 21, 2023

BUY
$30.35 - $53.15 $270,115 - $473,035
8,900 Added 8.5%
113,600 $5.62 Million
Q4 2022

Feb 14, 2023

BUY
$30.35 - $53.15 $3.45 Million - $6.04 Million
113,600 New
113,600 $5.62 Million

Others Institutions Holding EXAS

About EXACT SCIENCES CORP


  • Ticker EXAS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 176,960,000
  • Market Cap $8.73B
  • Description
  • Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for...
More about EXAS
Track This Portfolio

Track Jefferies Financial Group Inc. Portfolio

Follow Jefferies Financial Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jefferies Financial Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Jefferies Financial Group Inc. with notifications on news.